Zealand Pharma A/S (LON:0NZU)

Zealand Pharma Statistics

Total Valuation

Zealand Pharma has a market cap or net worth of GBP 4.27 billion. The enterprise value is 2.41 billion.

Market Cap	4.27B
Enterprise Value	2.41B

Important Dates

The last earnings date was Thursday, November 13, 2025.

Earnings Date	Nov 13, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	70.40M
Shares Outstanding	n/a
Shares Change (YoY)	+12.73%
Shares Change (QoQ)	-1.97%
Owned by Insiders (%)	0.38%
Owned by Institutions (%)	40.71%
Float	55.86M

Valuation Ratios

The trailing PE ratio is 5.59.

PE Ratio	5.59
Forward PE	n/a
PS Ratio	3.99
PB Ratio	2.41
P/TBV Ratio	2.41
P/FCF Ratio	4.96
P/OCF Ratio	4.95
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 2.88, with an EV/FCF ratio of 2.80.

EV / Earnings	3.15
EV / Sales	2.23
EV / EBITDA	2.88
EV / EBIT	2.88
EV / FCF	2.80

Financial Position

The company has a current ratio of 14.10, with a Debt / Equity ratio of 0.03.

Current Ratio	14.10
Quick Ratio	14.10
Debt / Equity	0.03
Debt / EBITDA	0.06
Debt / FCF	0.06
Interest Coverage	233.70

Financial Efficiency

Return on equity (ROE) is 54.42% and return on invested capital (ROIC) is 35.58%.

Return on Equity (ROE)	54.42%
Return on Assets (ROA)	33.44%
Return on Invested Capital (ROIC)	35.58%
Return on Capital Employed (ROCE)	45.27%
Revenue Per Employee	2.43M
Profits Per Employee	1.74M
Employee Count	335
Asset Turnover	0.69
Inventory Turnover	n/a

Taxes

In the past 12 months, Zealand Pharma has paid 66.95 million in taxes.

Income Tax	66.95M
Effective Tax Rate	8.05%

Stock Price Statistics

The stock price has decreased by -39.60% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-39.60%
50-Day Moving Average	468.31
200-Day Moving Average	473.27
Relative Strength Index (RSI)	56.07
Average Volume (20 Days)	33,244

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Zealand Pharma had revenue of GBP 1.07 billion and earned 764.70 million in profits. Earnings per share was 10.71.

Revenue	1.07B
Gross Profit	1.07B
Operating Income	826.37M
Pretax Income	831.65M
Net Income	764.70M
EBITDA	827.59M
EBIT	826.37M
Earnings Per Share (EPS)	10.71

Balance Sheet

The company has 1.89 billion in cash and 47.50 million in debt, giving a net cash position of 1.84 billion.

Cash & Cash Equivalents	1.89B
Total Debt	47.50M
Net Cash	1.84B
Net Cash Per Share	n/a
Equity (Book Value)	1.77B
Book Value Per Share	25.21
Working Capital	1.80B

Cash Flow

In the last 12 months, operating cash flow was 864.18 million and capital expenditures -2.07 million, giving a free cash flow of 862.11 million.

Operating Cash Flow	864.18M
Capital Expenditures	-2.07M
Free Cash Flow	862.11M
FCF Per Share	n/a

Margins

Gross margin is 99.99%, with operating and profit margins of 77.23% and 71.47%.

Gross Margin	99.99%
Operating Margin	77.23%
Pretax Margin	77.73%
Profit Margin	71.47%
EBITDA Margin	77.35%
EBIT Margin	77.23%
FCF Margin	80.57%

Dividends & Yields

Zealand Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.73%
Shareholder Yield	-12.73%
Earnings Yield	17.89%
FCF Yield	20.17%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Zealand Pharma has an Altman Z-Score of 17.81 and a Piotroski F-Score of 6.

Altman Z-Score	17.81
Piotroski F-Score	6